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Abstracts / Biol Blood Marrow Transplant 20 (2014) S72eS90S76up in survivors of 40months (range 2-80months), the 2-year
OS and PFS are 64% (95%CI: 47-86%) and 49% (95%CI: 32-
73%), respectively. In vivo T cell-depletionwith alemtuzumab
was associated with a markedly reduced 2-year PFS (0% vs
64%, p¼0.008) (Figure 1). Conversely, a sIPI at transplantation
<1 was associated with a much improved 2-year PFS (65% vs
13%, p¼0.021) compared to higher sIPI values (Figure 2).
Similarly, 2-year OS was also signiﬁcantly reduced with
alemtuzumab (33% vs 74%, p¼0.016) and in patients with sIPI
1 (39% vs 76%, p¼0.036).
Conclusions: RIC allo-SCT is a feasible and effective strategy
in patients with relapsed and refractory mantle cell lym-
phoma. High sIPI and use of alemtuzumab in the condi-
tioning regimen are associated with markedly inferior PFS.
Higher risk disease and the likely loss of graft-versus-lym-
phomawith alemtuzumab predict likelihood of failure of RIC
allo-SCT in relapsed and refractory MCL patients.80
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The treatment of advanced refractory DLBCL remains a major
challenge. High dose therapy with autologous stem cell
transplant (HDT/ASCT) has a limited role only in chemo-
sensitive relapsed disease, with a curative potential of 25-
50%. No therapy has proven to be effective long-term for
advanced chemo-refractory DLBCL. Although allo-HCT has
curative potential, historically, the outcomes remain unsat-
isfactory due to high treatment related mortality (TRM) after
myeloablative conditioning (MAC), high relapse rate after
reduced-intensity conditioning (RIC) regimens and theconcern for a less potent graft-versus-lymphoma effect (GVL)
A total of 97 DLBCL patients (pts) [M64:F33] undergoing allo-
HCT at UM between 1996 and 2011 were retrospectively
evaluated. The median age was 52 yrs (range, 23-70). Sev-
enty-four pts (76%) received a MAC [CVB in 49 pts (50%),
FluBu4 in 13 pts (13%), others in 12 (12%)]; 23 pts received
RIC with FluBu2 (24%); 79 pts (81%) were 8/8 HLA-matched.
Only 18 pts (19%) had prior HDT/ASCT. Donor sources were
58 related, 6 mismatched (MM), and 39 unrelated, 12 MM.
Stem cell sources were peripheral blood in 89%, bone
marrow in 10% and cord blood in 1%. GVHD prophylaxis was
tacrolimus/ mini-methotrexate in 71 pts (73%), tacrolimus/
MMF in 16 pts (17%) and others in 10 pts (10%). Fifty-ﬁve pts
(57%) had chemo-sensitive disease at transplant; 22 pts
(23%) had transformed DLBCL.
With a median follow-up time of 12 months (range, 1.6-194),
the cumulative incidences of grade 2-4, grade 3-4 acute
GVHD, chronic GVHD, TRM, relapse, OS and PFS were not
statistically different between the MAC and RIC cohorts
(Table). Relapse rate remained high in both groups. Chemo-
sensitivity, donor source and type of DLBCL had no impact on
survival.
In summary, allogeneic HCT for advanced DLCBL is feasible,
with acceptable TRM. Although, relapse is a major issue, allo-
HCT provides these heavily pretreated pts with a platform to
combine the GVL effect with other strategies tomaximize the
potential of long-term disease-free survival.PEDIATRIC DISORDERS81
Exposure of Thymoglobulin Is Associated with Overall
Survival in Children Receiving Allogeneic-Hematopoietic
Cell Transplantation (HCT): Towards Individualized
Dosing to Improve Survival
R. Admiraal 1, Cornelia M. Jol-van der Zijde 1,
Charlotte van Kesteren 2,3, Maarten van Tol 1,
